A method for determining whether a subject is at risk of developing a musculoskeletal disease; wherein the method comprises determining in a biological sample obtained from the subject a quantitative value of at least one biomarker of the following in the biological sample: - glycoprotein acetyls, - albumin, - a ratio of docosahexaenoic acid to total fatty acids, - a ratio of linoleic acid to total fatty acids - a ratio of monounsaturated fatty acids and/or of oleic acid to total fatty acids, - a ratio of omega-6 fatty acids to total fatty acids, - a ratio of saturated fatty acids to total fatty acids, - fatty acid degree of unsaturation, - docosahexaenoic acid, - linoleic acid, - monounsaturated fatty acids and/or oleic acid, - omega-6 fatty acids, - saturated fatty acids, - triglycerides in high-density lipoprotein, - triglycerides in low-density lipoprotein, - high-density lipoprotein particle size, - low-density lipoprotein particle size, - very-low-density lipoprotein (VLDL) particle size, - acetate, - citrate, - glutamine, - glycine, - histidine, - isoleucine, - leucine, - phenylalanine, - valine; and comparing the quantitative value(s) of the at least one biomarker to a control sample or to a control value; wherein an increase or a decrease in the quantitative value (s) of the at least one biomarker, when compared to the control sample or to the control value, is/are indicative of the subject having an increased risk of developing a musculoskeletal disease; wherein the at least one biomarker comprises or is glycoprotein acetyls; and wherein the musculoskeletal disease comprises or is osteoarthritis. wherein the method comprises determining in a biological sample obtained from the subject a quantitative value of at least one biomarker of the following in the biological sample: - glycoprotein acetyls, - albumin, - a ratio of docosahexaenoic acid to total fatty acids, - a ratio of linoleic acid to total fatty acids - a ratio of monounsaturated fatty acids and/or of oleic acid to total fatty acids, - a ratio of omega-6 fatty acids to total fatty acids, - a ratio of saturated fatty acids to total fatty acids, - fatty acid degree of unsaturation, - docosahexaenoic acid, - linoleic acid, - monounsaturated fatty acids and/or oleic acid, - omega-6 fatty acids, - saturated fatty acids, - triglycerides in high-density lipoprotein, - triglycerides in low-density lipoprotein, - high-density lipoprotein particle size, - low-density lipoprotein particle size, - very-low-density lipoprotein (VLDL) particle size, - acetate, - citrate, - glutamine, - glycine, - histidine, - isoleucine, - leucine, - phenylalanine, - valine; and - glycoprotein acetyls, - albumin, - a ratio of docosahexaenoic acid to total fatty acids, - a ratio of linoleic acid to total fatty acids - a ratio of monounsaturated fatty acids and/or of oleic acid to total fatty acids, - a ratio of omega-6 fatty acids to total fatty acids, - a ratio of saturated fatty acids to total fatty acids, - fatty acid degree of unsaturation, - docosahexaenoic acid, - linoleic acid, - monounsaturated fatty acids and/or oleic acid, - omega-6 fatty acids, - saturated fatty acids, - triglycerides in high-density lipoprotein, - triglycerides in low-density lipoprotein, - high-density lipoprotein particle size, - low-density lipoprotein particle size, - very-low-density lipoprotein (VLDL) particle size, - acetate, - citrate, - glutamine, - glycine, - histidine, - isoleucine, - leucine, - phenylalanine, - valine; and comparing the quantitative value(s) of the at least one biomarker to a control sample or to a control value; wherein an increase or a decrease in the quantitative value (s) of the at least one biomarker, when compared to the control sample or to the control value, is/are indicative of the subject having an increased risk of developing a musculoskeletal disease; wherein the at least one biomarker comprises or is glycoprotein acetyls; and wherein the musculoskeletal disease comprises or is osteoarthritis.